Eliapixant
Small moleculeexperimental
Clinical trial activity
17 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jul 22, 2016 (NCT02817100)
Timeline
Indications
Mechanism of action
- P2X purinoceptor 3ANTAGONIST
P2RX3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cnc(-c2cc(O[C@@H]3CCOC3)cc(C(=O)N[C@H](C)c3cnc(C(F)(F)F)nc3)c2)s1- Mol. weight
- 478.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095224 ↗
Also known as
- bay1817080
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04802343 | Phase 1 | Apr 2, 2021 | Bayer |
| NCT04614246 | Phase 2 | Jan 29, 2021 | Bayer |
| NCT04641273 | Phase 2 | Jan 22, 2021 | Bayer |
| NCT04562155 | Phase 2 | Oct 2, 2020 | Bayer |
| NCT04545580 | Phase 2 | Sep 16, 2020 | Bayer |
| NCT04471337 | Phase 1 | Aug 12, 2020 | Bayer |
| NCT04487431 | Phase 1 | Aug 5, 2020 | Bayer |
| NCT04454424 | Phase 1 | Jul 23, 2020 | Bayer |
| NCT04423744 | Phase 1 | Jun 22, 2020 | Bayer |
| NCT04265781 | Phase 1 | Feb 15, 2020 | Bayer |
| NCT04252300 | Phase 1 | Feb 12, 2020 | Bayer |
| NCT03789890 | Phase 1 | Jan 8, 2019 | Bayer |
| NCT03773068 | Phase 1 | Dec 13, 2018 | Bayer |
| NCT03535168 | Phase 1/Phase 2 (Phase 2) | May 29, 2018 | Bayer |
| NCT03310645 | Phase 1/Phase 2 (Phase 2) | Dec 7, 2017 | Bayer |
| NCT03212586 | Phase 1 | Jul 18, 2017 | Bayer |
| NCT02817100 | Phase 1 | Jul 22, 2016 | Bayer |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 17 | 17 | 2 | 2016 |
1 organizations
Page 1 / 1